Metoject

Methotrexate, the active ingredient in Metoject, is an antimetabolite (folate antagonist) presented as a solution for subcutaneous injection for subcutaneous use. It treats rheumatoid arthritis, psoriasis, severe plaque psoriasis, and certain malignancies such as acute lymphoblastic leukemia and non‑Hodgkin lymphoma in appropriate patients.

GNH USA supplies Metoject as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is a folate antagonist used in several immune‑mediated and oncologic conditions. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis (including severe plaque psoriasis): decreases skin cell proliferation and inflammation. - Acute lymphoblastic leukemia: interferes with malignant cell replication as part of chemotherapy protocols. - Non‑Hodgkin lymphoma: contributes to tumor control when combined with other agents.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Fatigue: general tiredness. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: mild hepatic irritation. - Low blood counts: mild leukopenia or anemia.

Serious or Rare Side Effects: - Severe liver toxicity: potential hepatitis or fibrosis. - Pulmonary fibrosis: interstitial lung disease. - Severe bone marrow suppression: pancytopenia. - Renal impairment: acute kidney injury. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing methotrexate, several precautions should be observed to minimize risks. - Pregnancy contraindication: avoid use in pregnancy (Category X) and discontinue well before conception. - Renal function monitoring: assess creatinine before initiation and periodically. - Liver function monitoring: perform baseline and regular liver enzyme tests. - Hematologic monitoring: check complete blood count regularly. - Concomitant NSAIDs caution: avoid combined use without supervision due to increased toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause severe infection. - High-dose aspirin or NSAIDs: increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: can enhance myelosuppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may increase serum methotrexate levels. - Azathioprine or other immunosuppressants: additive bone marrow suppression. - Oral contraceptives: may reduce methotrexate clearance.